publicationMetadata:
  pmid: "24786638"
  title: "Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer."
  queryType: "bench"
  publicationType: "Lab Research"
  publicationTypeConfidence: 0.95
  hasMethodsSection: Yes
  likelyContainsTools: Yes
  expectedToolTypes: |
    Lab Research → antibodies, cell lines, animal models, genetic reagents, computational tools, organoids, PDX
    
    This is a laboratory-based cancer research study investigating FAK inhibitor responsiveness in ovarian cancer cell lines.
    Expected tools include: cell lines (multiple ovarian cancer lines mentioned), genetic reagents (shRNA for knockdown),
    small molecule inhibitors, and potentially antibodies for immunoblotting. The study uses both in vitro cell culture
    and in vivo orthotopic tumor models, indicating comprehensive experimental approaches typical of cancer research.
  overallAssessment: |
    This publication represents classic laboratory cancer research with extensive experimental methodology. The study
    investigates drug responsiveness across multiple cell lines, uses genetic knockdown approaches, and employs both
    in vitro and in vivo model systems. Research tools are essential to this work and should be abundant throughout
    the methods and results sections.

toolValidations: []

potentiallyMissedTools:
  - toolName: "OVCAR8"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Greater than 50% inhibition of OVCAR8, HEY, and ID8-IP ovarian carcinoma cell growth occurred with 0.1 μM PF-271"
    whyMissed: "Standard ovarian cancer cell line name not detected by mining patterns"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "HEY"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Greater than 50% inhibition of OVCAR8, HEY, and ID8-IP ovarian carcinoma cell growth occurred with 0.1 μM PF-271"
    whyMissed: "Ovarian cancer cell line with non-standard naming convention"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "ID8-IP"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Greater than 50% inhibition of OVCAR8, HEY, and ID8-IP ovarian carcinoma cell growth occurred with 0.1 μM PF-271"
    whyMissed: "Murine ovarian cancer cell line with IP (intraperitoneal) designation"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "OVCAR3"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Standard ovarian cancer cell line name not detected"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "OVCAR10"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Standard ovarian cancer cell line name not detected"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "IGROV1"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Ovarian cancer cell line name not in mining patterns"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "IGROV1-IP"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Cell line variant with IP designation not recognized"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "SKOV3"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Well-known ovarian cancer cell line not detected"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "SKOV3-IP"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Cell line variant with IP designation not recognized"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "A2780"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Standard ovarian cancer cell line name not detected"
    confidence: 0.95
    shouldBeAdded: Yes

  - toolName: "5009-MOVCAR"
    toolType: "cell_line"
    foundIn: "abstract"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected"
    whyMissed: "Murine ovarian cancer cell line with non-standard naming"
    confidence: 0.90
    shouldBeAdded: Yes

  - toolName: "PF-271"
    toolType: "genetic_reagent"
    foundIn: "abstract"
    contextSnippet: "Nine human and two murine ovarian cancer cell lines were analyzed for growth in the presence of a small molecule FAK inhibitor (PF-271, also termed VS-6062)"
    whyMissed: "Small molecule inhibitor compound not recognized as genetic reagent/chemical tool"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "VS-6062"
    toolType: "genetic_reagent"
    foundIn: "abstract"
    contextSnippet: "small molecule FAK inhibitor (PF-271, also termed VS-6062)"
    whyMissed: "Alternative name for PF-271 inhibitor not detected"
    confidence: 0.85
    shouldBeAdded: Yes

  - toolName: "shRNA"
    toolType: "genetic_reagent"
    foundIn: "methods"
    contextSnippet: "Growth of cells was analyzed in an orthotopic tumor model and evaluated in vitro after stable shRNA-mediated merlin knockdown"
    whyMissed: "Generic shRNA term not specific enough for mining patterns"
    confidence: 0.80
    shouldBeAdded: Maybe

suggestedPatterns:
  - patternType: "naming_convention"
    pattern: "OVCAR[0-9]+"
    toolType: "cell_line"
    examples: ["OVCAR8", "OVCAR3", "OVCAR10"]
    reasoning: "OVCAR series are well-established ovarian cancer cell lines with consistent naming pattern"

  - patternType: "naming_convention"
    pattern: "SKOV3(-[A-Z]+)?"
    toolType: "cell_line"
    examples: ["SKOV3", "SKOV3-IP"]
    reasoning: "SKOV3 and its variants are commonly used ovarian cancer cell lines"

  - patternType: "naming_convention"
    pattern: "IGROV1(-[A-Z]+)?"
    toolType: "cell_line"
    examples: ["IGROV1", "IGROV1-IP"]
    reasoning: "IGROV1 series ovarian cancer cell lines with variant designations"

  - patternType: "naming_convention"
    pattern: "[A-Z0-9]+-[A-Z]+"
    toolType: "cell_line"
    examples: ["ID8-IP", "5009-MOVCAR"]
    reasoning: "Cell lines with hyphenated designations indicating variants or special characteristics"

  - patternType: "term"
    pattern: "A2780"
    toolType: "cell_line"
    examples: ["A2780"]
    reasoning: "Well-known ovarian cancer cell line that should be explicitly included"

  - patternType: "term"
    pattern: "HEY"
    toolType: "cell_line"
    examples: ["HEY"]
    reasoning: "Established ovarian cancer cell line with simple name that needs explicit inclusion"

  - patternType: "context_phrase"
    pattern: "small molecule.*inhibitor.*\\(([A-Z0-9-]+)"
    toolType: "genetic_reagent"
    examples: ["PF-271", "VS-6062"]
    reasoning: "Pattern to capture small molecule inhibitors mentioned with parenthetical compound names"

  - patternType: "context_phrase"
    pattern: "shRNA-mediated.*knockdown"
    toolType: "genetic_reagent"
    examples: ["shRNA-mediated merlin knockdown"]
    reasoning: "Context phrase indicating use of shRNA genetic reagents for gene knockdown"

observations:
  - resourceName: "OVCAR8"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Greater than 50% inhibition of cell growth occurred with 0.1 μM PF-271 in anchorage-independent culture conditions (p<0.001).
      This cell line showed high sensitivity to FAK inhibitor treatment specifically under suspended growth conditions,
      but not in adherent culture conditions. The differential response suggests dependency on FAK signaling for
      anchorage-independent survival.
    foundIn: "results"
    contextSnippet: "Greater than 50% inhibition of OVCAR8, HEY, and ID8-IP ovarian carcinoma cell growth occurred with 0.1 μM PF-271 in anchorage-independent (p<0.001) but not in adherent culture conditions"
    confidence: 0.95
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "HEY"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Greater than 50% inhibition of cell growth occurred with 0.1 μM PF-271 in anchorage-independent culture conditions (p<0.001).
      Similar to OVCAR8, this cell line demonstrated high sensitivity to FAK inhibition under suspended growth conditions
      but maintained normal growth in adherent conditions, indicating FAK-dependent anchorage-independent survival.
    foundIn: "results"
    contextSnippet: "Greater than 50% inhibition of OVCAR8, HEY, and ID8-IP ovarian carcinoma cell growth occurred with 0.1 μM PF-271 in anchorage-independent (p<0.001) but not in adherent culture conditions"
    confidence: 0.95
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "ID8-IP"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Greater than 50% inhibition of cell growth occurred with 0.1 μM PF-271 in anchorage-independent culture conditions (p<0.001).
      This murine ovarian cancer cell line showed similar FAK inhibitor sensitivity pattern as human cell lines,
      with growth inhibition specific to suspended culture conditions.
    foundIn: "results"
    contextSnippet: "Greater than 50% inhibition of OVCAR8, HEY, and ID8-IP ovarian carcinoma cell growth occurred with 0.1 μM PF-271 in anchorage-independent (p<0.001) but not in adherent culture conditions"
    confidence: 0.95
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "OVCAR3"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Suspended growth was not affected by 0.1 μM PF-271 treatment. This cell line demonstrated resistance to
      FAK inhibitor treatment, showing no significant growth inhibition under anchorage-independent conditions
      that were effective against OVCAR8, HEY, and ID8-IP cells.
    foundIn: "results"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected by 0.1 μM PF-271"
    confidence: 0.90
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "OVCAR10"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Suspended growth was not affected by 0.1 μM PF-271 treatment. Merlin knockdown in OVCAR10 cells did not
      alter suspended cell growth upon PF-271 addition, indicating that merlin levels do not determine FAK
      inhibitor sensitivity in this cell line.
    foundIn: "results"
    contextSnippet: "Suspended growth of OVCAR3, OVCAR10, IGROV1, IGROV1-IP, SKOV3, SKOV3-IP, A2780, and 5009-MOVCAR was not affected by 0.1 μM PF-271"
    confidence: 0.90
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "SKOV3-IP"
    resourceType: "Cell Line"
    observationType: "Cellular"
    observationTypeOntologyId: "MP:0005384"
    details: |
      Suspended growth was not affected by 0.1 μM PF-271 treatment. Merlin knockdown in SKOV3-IP cells did not
      alter suspended cell growth upon PF-271 addition, demonstrating that reducing merlin expression does not
      induce sensitivity to FAK inhibition in this resistant cell line.
    foundIn: "results"
    contextSnippet: "merlin knockdown in SKOV3-IP and OVCAR10 cells did not alter suspended cell growth upon PF-271 addition"
    confidence: 0.90
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "5009-MOVCAR"
    resourceType: "Cell Line"
    observationType: "Tumor Growth"
    observationTypeOntologyId: "MP:0002006"
    details: |
      PF-271 treatment (30 mg/kg, BID) did not inhibit tumor growth in an orthotopic model. This murine ovarian
      cancer cell line demonstrated resistance to FAK inhibitor treatment both in vitro and in vivo, indicating
      FAK-independent growth mechanisms.
    foundIn: "results"
    contextSnippet: "PF-271 (30 mg/kg, BID) did not inhibit 5009-MOVCAR tumor growth"
    confidence: 0.85
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "PF-271"
    resourceType: "Genetic Reagent"
    observationType: "Molecular"
    observationTypeOntologyId: "MP:0010768"
    details: |
      PF-271-mediated reduction in FAK Y397 phosphorylation occurred independently of growth inhibition.
      The compound effectively inhibited FAK phosphorylation at the Y397 autophosphorylation site across
      cell lines regardless of their growth response, indicating target engagement but variable downstream effects.
    foundIn: "results"
    contextSnippet: "PF-271-mediated reduction in FAK Y397 phosphorylation occurred independently of growth inhibition"
    confidence: 0.90
    doi: "10.1016/j.ygyno.2014.04.044"

  - resourceName: "PF-271"
    resourceType: "Genetic Reagent"
    observationType: "Usage Instructions"
    observationTypeOntologyId: ""
    details: |
      Intrinsic low merlin protein levels correlated with PF-271-mediated anchorage-independent growth inhibition.
      Merlin levels may be useful for patient stratification in FAK inhibitor trials. The compound showed differential
      efficacy based on culture conditions, with effectiveness limited to anchorage-independent growth conditions.
    foundIn: "discussion"
    contextSnippet: "Intrinsic low merlin protein levels correlated with PF-271-mediated anchorage-independent growth inhibition, but reduction in merlin expression did not induce sensitivity to FAK inhibition. Merlin levels may be useful for patient stratification in FAK inhibitor trials"
    confidence: 0.85
    doi: "10.1016/j.ygyno.2014.04.044"

summary:
  totalToolsMined: 0
  toolsAccepted: 0
  toolsRejected: 0
  toolsUncertain: 0
  potentiallyMissedCount: 13
  newPatternsCount: 8
  observationsExtracted: 8
  observationsByType:
    Cellular: 5
    Tumor Growth: 1
    Molecular: 1
    Usage Instructions: 1
  majorIssuesFound: |
    - Complete failure of mining system to detect any tools despite publication being rich in research tools
    - Multiple well-established cell lines (OVCAR8, HEY, SKOV3, A2780, etc.) completely missed
    - Small molecule inhibitor compounds (PF-271/VS-6062) not detected
    - Genetic reagents (shRNA) not identified
    - Mining patterns appear inadequate for cancer cell line nomenclature
  recommendations: |
    This publication represents a significant mining failure - 13 legitimate research tools were completely missed
    while 0 tools were initially detected. The study is a classic laboratory cancer research paper with extensive
    use of cell lines, chemical inhibitors, and genetic reagents. All missed tools should be added to the database.
    
    Critical pattern improvements needed:
    1. Enhanced cell line detection for OVCAR, SKOV3, IGROV1 series
    2. Better recognition of hyphenated cell line variants (ID8-IP, SKOV3-IP)
    3. Small molecule inhibitor detection with compound codes (PF-271, VS-6062)
    4. Context-based shRNA reagent identification
    
    The extracted observations provide valuable information about FAK inhibitor responsiveness, merlin protein
    correlations, and differential cell line sensitivities that would be useful for the research community.
    This publication should be flagged for complete re-mining with improved patterns.
